Migraine PowerPlug: Migraine is one of the most common and at the same time most underestimated neurological disorders worldwide. With the increasing importance of wearables and digital health, new ways are opening up to better support sufferers in their everyday lives. Ultrahuman and Click Therapeutics are now jointly introducing the Migraine PowerPlug – an innovative solution that combines data from a smart ring with an FDA-approved digital therapy for the first time. The aim is not only to detect migraines, but also to provide active and personalized support.
- Combination of Ultrahuman Smart Ring and FDA-approved digital migraine therapy
- Real-time analysis of sleep, HRV, stress and movement to identify triggers
- Personalized, scientifically based recommendations for action in everyday life
Migraine PowerPlug: How the smart ring approach sets new standards
With the Migraine PowerPlug, Ultrahuman and Click Therapeutics are significantly expanding the functional scope of modern wearables. The focus is not on the ring as a medical device, but on the intelligent use of its biometric data within a software-based, clinically validated therapy. The basis is the CT-132 digital therapy system from Click Therapeutics, the first and so far only digital treatment for preventive migraine therapy approved by the US Food and Drug Administration (FDA).
The Ultrahuman Ring continuously records relevant parameters such as sleep quality, heart rate variability (HRV), stress level and activity. This data is analyzed in the Ultrahuman app and linked to Click Therapeutics’ evidence-based therapy principles. In contrast to traditional tracking solutions, this creates a dynamic model that makes the connections between lifestyle, biological changes and migraine events visible.
This approach is particularly relevant for women, who according to studies are significantly more frequently affected by migraines. Hormonal fluctuations play a central role in this. Ultrahuman has already strategically anchored this aspect and is continuously expanding its offering with cycle- and hormone-based analyses. The Migraine PowerPlug fits seamlessly into this ecosystem and addresses a condition that has so far often only been treated selectively in medical consultations, but is permanently present in everyday life.
Migraine PowerPlug: digital therapy meets personalized everyday data
The Migraine PowerPlug is pursuing a clear paradigm shift: away from purely reactive treatment and towards continuous prevention and behavioral support. Instead of just documenting symptoms, the system provides specific, personalized action plans. These include sleep goals, exercise recommendations and individual advice on fluid intake – always adapted to the patterns recognized by the respective user.
A key added value lies in the translation of complex health data into understandable, actionable guidelines. Users can see which factors contribute to their migraines and how small adjustments in everyday life can have a long-term effect on the frequency and intensity of attacks. Click Therapeutics’ digital therapy is expressly designed to complement existing medication and is clinically designed to reduce the overall burden of migraines.
This partnership marks an important step for the wearable market: for the first time, an FDA-approved digital migraine therapy is combined directly with continuously collected biomarkers from a smart ring. Ultrahuman is thus positioning itself not only as a hardware provider, but also as a platform for evidence-based, digital health applications that go beyond traditional fitness tracking.
Conclusion
With the Migraine PowerPlug, Ultrahuman and Click Therapeutics are demonstrating how wearables and digital therapies can be meaningfully interlinked. The approach is plausible, as it is based on FDA-approved software and combines this with established biometric measurement data. Following a pilot phase, the Migraine PowerPlug should be available via the Ultrahuman app in early 2026, including in Europe, the USA and Canada. Information on the price is still pending, but is likely to be based on the existing Ultrahuman subscription.
